BBPETF / FundVirtus Biotech Etf
Verdicts genuinely change. Free email alert the moment BBP's does — no target price to set, unlike a price alert.
Whether this fund clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
Virtus Biotech Etf ETF · ETFis Series Trust I
70 holdings · as of 2026-07-31 (3.6 months ago) The fund may have traded since. SEC Form N-PORT is filed quarterly and lags the period it covers, so these are the most recent holdings on file, not the fund’s holdings today.
This fund holds short positions, so exposure is counted gross — long and short both count as exposure rather than netting off, and the weights below therefore sum to 101% of net assets rather than 100%. Shares of the portfolio are shown as shares of that gross exposure.
NON-COMPLIANT 40.55% of portfolio weight is in non-compliant holdings, over the 5% threshold.
70 holdings, 62 matched (87% of weight). Portfolio as of 2026-07-31, filed 2026-09-29. Source: SEC Form N-PORT.
7.47% of this portfolio’s income is non-permissible — weighted across holdings, computed over 83% of portfolio weight (59 of 70 holdings). The common approach purifies that proportion of income received — dividends — not of the position’s value. We report the ratio; what to do with it is a question for your own scholar.
46.6% compliant 0.0% questionable 40.3% non-compliant 13.1% unscreened
All holdings (70)
| Holding | Status | Weight | Every methodology, and the debt ratio behind it |
|---|---|---|---|
| CRINETICS PHARMACEUTICALS INC | UNSCREENED | 3.34% | no in-house ratios for this holding |
| KNSA KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | COMPLIANT | 1.97% | AAOIFI0.1% Usmani0.8% Dow Jones Islamic0.2% S&P Shariah0.3% MSCI Islamic0.8% MSCI Islamic M-Series0.3% FTSE Shariah0.0% |
| VSTM VERASTEM INC | NON_COMPLIANT | 1.95% | AAOIFI6.3% Usmani16.1% Dow Jones Islamic8.5% S&P Shariah10.1% MSCI Islamic16.1% MSCI Islamic M-Series10.1% FTSE Shariah14.8% |
| PGEN PRECIGEN INC | NON_COMPLIANT | 1.94% | AAOIFI6.4% Usmani46.5% Dow Jones Islamic8.2% S&P Shariah10.8% MSCI Islamic46.5% MSCI Islamic M-Series10.8% FTSE Shariah44.4% |
| OMEROS CORP | UNSCREENED | 1.87% | no in-house ratios for this holding |
| NUVB NUVATION BIO INC | NON_COMPLIANT | 1.77% | AAOIFI21.7% Usmani38.6% Dow Jones Islamic20.6% S&P Shariah25.7% MSCI Islamic38.6% MSCI Islamic M-Series25.7% FTSE Shariah36.7% |
| REGN REGENERON PHARMACEUTICALS | COMPLIANT | 1.72% | AAOIFI2.0% Usmani6.1% Dow Jones Islamic3.1% S&P Shariah2.7% MSCI Islamic4.5% MSCI Islamic M-Series2.7% FTSE Shariah4.5% |
| PTGX PROTAGONIST THERAPEUTICS INC | NON_COMPLIANT | 1.71% | AAOIFI0.1% Usmani0.8% Dow Jones Islamic0.2% S&P Shariah0.2% MSCI Islamic0.8% MSCI Islamic M-Series0.2% FTSE Shariah0.0% |
| ACAD ACADIA PHARMACEUTICALS INC | COMPLIANT | 1.69% | AAOIFI2.3% Usmani4.0% Dow Jones Islamic1.9% S&P Shariah2.0% MSCI Islamic4.0% MSCI Islamic M-Series2.0% FTSE Shariah0.0% |
| BBIO BRIDGEBIO PHARMA INC | COMPLIANT | 1.65% | AAOIFI17.4% Usmani122.4% Dow Jones Islamic24.2% S&P Shariah29.2% MSCI Islamic122.4% MSCI Islamic M-Series29.2% FTSE Shariah121.7% |
| ONC BEONE MEDICINES LTD | COMPLIANT | 1.65% | AAOIFI2.8% Usmani12.5% Dow Jones Islamic0.3% S&P Shariah0.3% MSCI Islamic12.5% MSCI Islamic M-Series0.3% FTSE Shariah11.7% |
| XERS XERIS BIOPHARMA HOLDINGS INC | COMPLIANT | 1.64% | AAOIFI19.9% Usmani70.3% Dow Jones Islamic30.4% S&P Shariah39.2% MSCI Islamic70.3% MSCI Islamic M-Series39.2% FTSE Shariah61.3% |
| HALO HALOZYME THERAPEUTICS INC | COMPLIANT | 1.64% | AAOIFI29.5% Usmani93.6% Dow Jones Islamic38.6% S&P Shariah42.8% MSCI Islamic93.6% MSCI Islamic M-Series42.8% FTSE Shariah93.6% |
| LQDA LIQUIDIA CORP | COMPLIANT | 1.63% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| IMCR IMMUNOCORE HOLDINGS PLC | NON_COMPLIANT | 1.61% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariah— MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| IRWD IRONWOOD PHARMACEUTICALS INC | NON_COMPLIANT | 1.60% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahpass MSCI Islamicfail MSCI Islamic M-Seriespass FTSE Shariahfail |
| ARWR ARROWHEAD PHARMACEUTICALS INC | COMPLIANT | 1.56% | AAOIFI11.9% Usmani46.3% Dow Jones Islamic12.9% S&P Shariah15.5% MSCI Islamic46.3% MSCI Islamic M-Series15.5% FTSE Shariah39.3% |
| ROIVANT SCIENCES LTD | UNSCREENED | 1.55% | no in-house ratios for this holding |
| LGND LIGAND PHARMACEUTICALS | COMPLIANT | 1.55% | AAOIFI19.7% Usmani51.8% Dow Jones Islamic34.1% S&P Shariah42.6% MSCI Islamic51.8% MSCI Islamic M-Series42.6% FTSE Shariah51.5% |
| RYTM RHYTHM PHARMACEUTICALS INC | NON_COMPLIANT | 1.55% | AAOIFI1.3% Usmani24.0% Dow Jones Islamic1.9% S&P Shariah2.3% MSCI Islamic24.0% MSCI Islamic M-Series2.3% FTSE Shariah23.2% |
| GERN GERON CORP | NON_COMPLIANT | 1.54% | AAOIFI20.0% Usmani23.0% Dow Jones Islamic11.6% S&P Shariah8.9% MSCI Islamic23.0% MSCI Islamic M-Series8.9% FTSE Shariah22.8% |
| RIGL RIGEL PHARMACEUTICALS INC | COMPLIANT | 1.54% | AAOIFIpass Usmanipass Dow Jones Islamicpass S&P Shariahpass MSCI Islamicpass MSCI Islamic M-Seriespass FTSE Shariahpass |
| ASND ASCENDIS PHARMA A/S | COMPLIANT | 1.54% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| ARQT ARCUTIS BIOTHERAPEUTICS INC | COMPLIANT | 1.52% | AAOIFI3.2% Usmani21.9% Dow Jones Islamic4.5% S&P Shariah5.8% MSCI Islamic21.9% MSCI Islamic M-Series5.8% FTSE Shariah20.9% |
| INCY INCYTE CORP | COMPLIANT | 1.52% | AAOIFI0.0% Usmani0.5% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.1% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| CYTK CYTOKINETICS INC | NON_COMPLIANT | 1.51% | AAOIFI7.3% Usmani29.6% Dow Jones Islamic7.7% S&P Shariah8.0% MSCI Islamic29.6% MSCI Islamic M-Series8.0% FTSE Shariah22.9% |
| MRNA MODERNA INC | NON_COMPLIANT | 1.51% | AAOIFI1.5% Usmani9.4% Dow Jones Islamic5.4% S&P Shariah4.5% MSCI Islamic9.2% MSCI Islamic M-Series4.5% FTSE Shariah4.4% |
| AMGN AMGEN INC | COMPLIANT | 1.49% | AAOIFI21.4% Usmani56.2% Dow Jones Islamic31.0% S&P Shariah32.5% MSCI Islamic56.2% MSCI Islamic M-Series32.5% FTSE Shariah56.2% |
| TVTX TRAVERE THERAPEUTICS INC | COMPLIANT | 1.48% | AAOIFI10.0% Usmani77.2% Dow Jones Islamic24.4% S&P Shariah32.6% MSCI Islamic77.2% MSCI Islamic M-Series32.6% FTSE Shariah75.4% |
| KRYS KRYSTAL BIOTECH INC | NON_COMPLIANT | 1.48% | AAOIFI0.1% Usmani0.5% Dow Jones Islamic0.1% S&P Shariah0.1% MSCI Islamic0.5% MSCI Islamic M-Series0.1% FTSE Shariah0.0% |
| VRTX VERTEX PHARMACEUTICALS INC | COMPLIANT | 1.48% | AAOIFI1.6% Usmani7.2% Dow Jones Islamic1.7% S&P Shariah1.7% MSCI Islamic7.2% MSCI Islamic M-Series1.7% FTSE Shariah0.0% |
| BMRN BIOMARIN PHARMACEUTICAL INC | NON_COMPLIANT | 1.48% | AAOIFI37.0% Usmani36.1% Dow Jones Islamic36.6% S&P Shariah32.3% MSCI Islamic36.1% MSCI Islamic M-Series32.3% FTSE Shariah36.1% |
| 9688.HK ZAI LAB LTD | NON_COMPLIANT | 1.47% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahfail MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| MIRM MIRUM PHARMACEUTICALS INC | COMPLIANT | 1.47% | AAOIFI12.4% Usmani72.4% Dow Jones Islamic17.9% S&P Shariah22.7% MSCI Islamic72.4% MSCI Islamic M-Series22.7% FTSE Shariah71.2% |
| DENALI THERAPEUTICS INC | UNSCREENED | 1.46% | no in-house ratios for this holding |
| TGTX TG THERAPEUTICS INC | COMPLIANT | 1.45% | AAOIFI7.7% Usmani47.4% Dow Jones Islamic12.6% S&P Shariah15.3% MSCI Islamic47.4% MSCI Islamic M-Series15.3% FTSE Shariah46.8% |
| NBIX NEUROCRINE BIOSCIENCES INC | COMPLIANT | 1.44% | AAOIFI2.7% Usmani8.0% Dow Jones Islamic3.3% S&P Shariah3.3% MSCI Islamic8.0% MSCI Islamic M-Series3.3% FTSE Shariah0.0% |
| SNDX SYNDAX PHARMACEUTICALS INC | NON_COMPLIANT | 1.44% | AAOIFI71.8% Usmani85.9% Dow Jones Islamic41.2% S&P Shariah39.2% MSCI Islamic85.9% MSCI Islamic M-Series39.2% FTSE Shariah85.8% |
| GILD GILEAD SCIENCES INC | COMPLIANT | 1.43% | AAOIFI12.6% Usmani51.0% Dow Jones Islamic17.6% S&P Shariah20.4% MSCI Islamic51.0% MSCI Islamic M-Series20.4% FTSE Shariah51.0% |
| BCRX BIOCRYST PHARMACEUTICALS INC | NON_COMPLIANT | 1.42% | AAOIFI21.1% Usmani68.8% Dow Jones Islamic21.3% S&P Shariah23.8% MSCI Islamic68.5% MSCI Islamic M-Series23.8% FTSE Shariah66.9% |
| ADMA ADMA BIOLOGICS INC | COMPLIANT | 1.42% | AAOIFI6.7% Usmani27.7% Dow Jones Islamic5.7% S&P Shariah6.4% MSCI Islamic27.7% MSCI Islamic M-Series6.4% FTSE Shariah26.7% |
| ULTRAGENYX PHARMACEUTICAL IN | UNSCREENED | 1.41% | no in-house ratios for this holding |
| HRMY HARMONY BIOSCIENCES HOLDINGS INC | NON_COMPLIANT | 1.41% | AAOIFI8.0% Usmani10.5% Dow Jones Islamic7.9% S&P Shariah8.0% MSCI Islamic10.5% MSCI Islamic M-Series8.0% FTSE Shariah10.1% |
| AGIO AGIOS PHARMACEUTICALS INC | NON_COMPLIANT | 1.40% | AAOIFI1.4% Usmani2.5% Dow Jones Islamic1.3% S&P Shariah1.3% MSCI Islamic2.5% MSCI Islamic M-Series1.3% FTSE Shariah0.0% |
| BIIB BIOGEN INC | COMPLIANT | 1.40% | AAOIFI19.7% Usmani23.1% Dow Jones Islamic29.8% S&P Shariah27.2% MSCI Islamic23.1% MSCI Islamic M-Series27.2% FTSE Shariah22.7% |
| THERAVANCE BIOPHARMA INC | UNSCREENED | 1.40% | no in-house ratios for this holding |
| IBRX IMMUNITYBIO INC | COMPLIANT | 1.39% | AAOIFIpass Usmanifail Dow Jones Islamic— S&P Shariah— MSCI Islamicfail MSCI Islamic M-Series— FTSE Shariahfail |
| INSMED INC | UNSCREENED | 1.39% | no in-house ratios for this holding |
| 22UA.DE BIONTECH SE | NON_COMPLIANT | 1.38% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahfail MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| EXEL EXELIXIS INC | COMPLIANT | 1.37% | AAOIFI1.0% Usmani6.5% Dow Jones Islamic1.4% S&P Shariah1.6% MSCI Islamic6.5% MSCI Islamic M-Series1.6% FTSE Shariah0.0% |
| IOVA IOVANCE BIOTHERAPEUTICS INC | COMPLIANT | 1.37% | AAOIFI1.3% Usmani4.6% Dow Jones Islamic2.5% S&P Shariah2.1% MSCI Islamic4.6% MSCI Islamic M-Series2.1% FTSE Shariah0.0% |
| KURA KURA ONCOLOGY INC | NON_COMPLIANT | 1.37% | AAOIFI3.8% Usmani4.6% Dow Jones Islamic3.4% S&P Shariah2.6% MSCI Islamic4.6% MSCI Islamic M-Series2.6% FTSE Shariah1.7% |
| MDGL MADRIGAL PHARMACEUTICALS INC | COMPLIANT | 1.34% | AAOIFI3.6% Usmani24.7% Dow Jones Islamic3.7% S&P Shariah4.4% MSCI Islamic24.7% MSCI Islamic M-Series4.4% FTSE Shariah23.8% |
| SRPT SAREPTA THERAPEUTICS INC | NON_COMPLIANT | 1.34% | AAOIFI76.5% Usmani38.2% Dow Jones Islamic31.7% S&P Shariah18.8% MSCI Islamic38.2% MSCI Islamic M-Series18.8% FTSE Shariah32.1% |
| CRSP CRISPR THERAPEUTICS AG | NON_COMPLIANT | 1.33% | AAOIFI19.9% Usmani30.5% Dow Jones Islamic16.6% S&P Shariah16.4% MSCI Islamic30.5% MSCI Islamic M-Series16.4% FTSE Shariah23.0% |
| ZYME ZYMEWORKS INC | NON_COMPLIANT | 1.32% | AAOIFI19.4% Usmani33.3% Dow Jones Islamic27.5% S&P Shariah32.8% MSCI Islamic33.3% MSCI Islamic M-Series32.8% FTSE Shariah28.8% |
| TARS TARSUS PHARMACEUTICALS INC | COMPLIANT | 1.31% | AAOIFI2.3% Usmani14.5% Dow Jones Islamic3.8% S&P Shariah4.7% MSCI Islamic14.5% MSCI Islamic M-Series4.7% FTSE Shariah11.9% |
| UTHR UNITED THERAPEUTICS CORP | NON_COMPLIANT | 1.31% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| AUPH AURINIA PHARMACEUTICALS INC | COMPLIANT | 1.30% | AAOIFI0.2% Usmani7.1% Dow Jones Islamic0.2% S&P Shariah0.2% MSCI Islamic0.4% MSCI Islamic M-Series0.2% FTSE Shariah0.0% |
| PTCT PTC THERAPEUTICS INC | NON_COMPLIANT | 1.25% | AAOIFI13.7% Usmani21.6% Dow Jones Islamic15.9% S&P Shariah18.7% MSCI Islamic21.5% MSCI Islamic M-Series18.7% FTSE Shariah18.4% |
| ARDX ARDELYX INC | NON_COMPLIANT | 1.20% | AAOIFI33.0% Usmani43.6% Dow Jones Islamic20.3% S&P Shariah18.8% MSCI Islamic43.6% MSCI Islamic M-Series18.8% FTSE Shariah43.0% |
| AXSM AXSOME THERAPEUTICS INC | COMPLIANT | 1.18% | AAOIFI2.9% Usmani27.1% Dow Jones Islamic2.8% S&P Shariah3.3% MSCI Islamic25.3% MSCI Islamic M-Series3.3% FTSE Shariah22.7% |
| PHAT PHATHOM PHARMACEUTICALS INC | NON_COMPLIANT | 1.16% | AAOIFI37.6% Usmani48.7% Dow Jones Islamic23.5% S&P Shariah24.1% MSCI Islamic48.7% MSCI Islamic M-Series24.1% FTSE Shariah48.0% |
| NVAX NOVAVAX INC | NON_COMPLIANT | 1.14% | AAOIFI22.2% Usmani33.3% Dow Jones Islamic21.5% S&P Shariah21.8% MSCI Islamic32.9% MSCI Islamic M-Series21.8% FTSE Shariah32.9% |
| ALNY ALNYLAM PHARMACEUTICALS INC | COMPLIANT | 1.00% | AAOIFI1.1% Usmani3.1% Dow Jones Islamic0.6% S&P Shariah0.7% MSCI Islamic3.1% MSCI Islamic M-Series0.7% FTSE Shariah0.0% |
| IONS IONIS PHARMACEUTICALS INC | NON_COMPLIANT | 0.97% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahfail MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| LEGN LEGEND BIOTECH CORP | COMPLIANT | 0.71% | AAOIFI8.8% Usmani18.4% Dow Jones Islamic2.9% S&P Shariah2.3% MSCI Islamic18.4% MSCI Islamic M-Series2.3% FTSE Shariah18.4% |
| DREYFUS GOVERNMENT CASH MANAGE | UNSCREENED | 0.71% | no in-house ratios for this holding |
| OABI OMNIAB INC | NON_COMPLIANT | 0.00% | AAOIFI2.5% Usmani6.2% Dow Jones Islamic5.3% S&P Shariah4.4% MSCI Islamic6.2% MSCI Islamic M-Series4.4% FTSE Shariah0.0% |
| OABI OMNIAB INC | NON_COMPLIANT | 0.00% | AAOIFI2.5% Usmani6.2% Dow Jones Islamic5.3% S&P Shariah4.4% MSCI Islamic6.2% MSCI Islamic M-Series4.4% FTSE Shariah0.0% |
The published standards disagree about this fund by 43 points of portfolio weight — 49.0% of it passes S&P Shariah, 5.7% passes MSCI Islamic. Which number is yours depends on which standard you follow.
These bars are the financial-ratio result under each standard — debt, receivables and interest income. They do not screen what the business does, so a holding can pass every ratio here and still be questionable or non-compliant on activity. The blended verdict above accounts for both.
ratios pass on 43.4% ratios fail on 38.1% 19.0% not rated under AAOIFI
ratios pass on 10.1% ratios fail on 71.5% 18.9% not rated under Usmani
ratios pass on 45.1% ratios fail on 35.6% 19.8% not rated under Dow Jones Islamic
ratios pass on 49.0% ratios fail on 30.1% 21.4% not rated under S&P Shariah
ratios pass on 5.7% ratios fail on 76.1% 18.7% not rated under MSCI Islamic
ratios pass on 46.5% ratios fail on 34.2% 19.8% not rated under MSCI Islamic M-Series
ratios pass on 10.1% ratios fail on 71.5% 18.9% not rated under FTSE Shariah
61 of 70 listed holdings carry our own per-methodology verdicts (87% of weight). The rest hold a provider verdict with no methodology breakdown, and are counted as rated by none. Of those, 53 (76% of weight) also carry the underlying debt ratio; the rest show a verdict without the figure behind it.
| Non-compliant holding | Weight |
|---|---|
| VSTM VERASTEM INC | 1.95% |
| PGEN PRECIGEN INC | 1.94% |
| NUVB NUVATION BIO INC | 1.77% |
| PTGX PROTAGONIST THERAPEUTICS INC | 1.71% |
| IMCR IMMUNOCORE HOLDINGS PLC | 1.61% |
| IRWD IRONWOOD PHARMACEUTICALS INC | 1.60% |
| RYTM RHYTHM PHARMACEUTICALS INC | 1.55% |
| GERN GERON CORP | 1.54% |
| CYTK CYTOKINETICS INC | 1.51% |
| MRNA MODERNA INC | 1.51% |
Methodology breakdown computing — it will appear here on its own.
Trade setup
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
Why this signal?
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
Virtus Biotech Etf (BBP) is currently considered not halal (non-compliant), per our own look-through to its filed holdings. See its filed holdings and the weight breakdown below for the reasoning.
🕌 In-house Compliance Research
Computing the full ratio and business-activity breakdown for BBP — this runs off the critical path so the page paints first. It will appear here on its own.
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Ken Griffin | Citadel Advisors | $3M | 0.0% | 2026-09-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 39.30 | NEUTRAL |
| Stochastic %K (14) | 10.43 | BUY |
| CCI (20) | -194.70 | BUY |
| Williams %R (14) | -89.57 | BUY |
| MACD (12,26,9) | -0.61 | SELL |
| ROC (10) | -7.00 | SELL |
| Momentum (10) | -7.38 | SELL |
| EMA (10) | 101.14 | SELL |
| SMA (10) | 101.68 | SELL |
| EMA (20) | 102.18 | SELL |
| SMA (20) | 102.83 | SELL |
| EMA (30) | 102.61 | SELL |
| SMA (30) | 102.89 | SELL |
| EMA (50) | 102.67 | SELL |
| SMA (50) | 103.30 | SELL |
| EMA (100) | 100.57 | SELL |
| SMA (100) | 102.37 | SELL |
| EMA (200) | 93.99 | BUY |
| SMA (200) | 93.75 | BUY |
About Virtus Biotech Etf
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration ("FDA") for marketing.
Background via Yahoo Finance — informational, not part of the verdict.
Weak — low conviction, small size or skip
SMC — Top Down
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 43 |
| 🕐 1H | BEARISH | 36 |
| ⏱ 15-Min | BEARISH | 130 |
| ⏲ 5-Min | RANGING | 234 |
Momentum & Volume
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
Peer Movement
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
Before you act on this
The questions worth asking about any verdict on this page, answered plainly.
Is a fund screened on its name?
No. HTR reads the fund's filed holdings and screens each one, then reports the result by weight. A fund marketed as Islamic still gets the same look-through as any other.
What does unrated weight mean?
It is the share of the fund whose holdings HTR cannot cover far enough to rate. It is reported as unrated rather than counted as compliant, because a holding nobody screened should not look like one that passed.
Does the issuer's board make it compliant?
It matters, and it is noted, but it does not replace the look-through. The board's judgement and the holdings screen are shown separately so you can see when they agree and when they do not.
How often is this re-screened?
When the fund files new holdings, and on a rolling basis besides. The date on the verdict above is the last time this fund was actually recomputed.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Compare with
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider Activity (90d)
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
NO DATA 0 buys · 0 sells
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-11-10 · Asset managers net 914130 (-14454)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.